TriSalus Life Sciences (TLSI) Asset Writedowns and Impairment (2024 - 2025)
TriSalus Life Sciences' (TLSI) quarterly Asset Writedowns and Impairment came in at $34000.0 in Q3 2025, down 40.35% quarter-over-quarter from $57000.0 in Q2 2025.
TriSalus Life Sciences (TLSI) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
TriSalus Life Sciences' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $34000.0 for Q3 2025.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $34000.0 in Q3 2025; TTM through Sep 2025 was $317000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $187000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment eased to $34000.0 in Q3 2025 per TLSI's latest filing, from $57000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $187000.0 in Q4 2024 and bottomed at $34000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.91 Bn | 176.62 Bn | 6.27 Bn |
| 2 | Stryker | 128.87 Bn | 125.99 Bn | 3.81 Bn |
| 3 | Medtronic | 108.72 Bn | 99.50 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.46 Bn | 67.01 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.53 Bn | 44.85 Bn | 1.29 Bn |
| 6 | Dexcom | 28.37 Bn | 27.25 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - |
| 9 | Koninklijke Philips | 25.47 Bn | 22.34 Bn | 2.07 Bn |
| 10 | TriSalus Life Sciences | 222.14 Mn | 165.58 Mn | 7.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 34,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 39,000.00 |
| Mar 31, 2025 | 39,000.00 |
| Dec 31, 2024 | 187,000.00 |
| Dec 31, 2024 | 187,000.00 |